About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
Is Wheels Up Experience a Buy Under $5?
Wheels Up Experience (UP) is the first publicly traded private aviation company. However, despite reporting a 55% year-over-year rise in revenues in the last quarter, the stock has declined 43.1% over the past month. Currently, trading under $5, is UP an ideal investment now? Read more to find out.
Is Rocket Lab a Good Aerospace Stock to Add to Your Portfolio?
Space company Rocket Lab USA (RKLB) is a leading satellite launcher globally. It has gained in double digits since its stock market debut on August 25. However, given its stretched valuation and negative profit margins, is RKLB a good investment now?
Should You Buy the Dip in SoFi Technologies Under $20?
Personal finance start-up SoFi Technologies (SOFI) went public through a reverse merger on June 1, 2021. However, the stock’s price has since slumped. But, with a favorable revenue growth outlook, is SOFI an ideal investment now? Read more to find out.
Is Express Inc. a Buy After Beating Q3 Earnings Estimates?
The shares of specialty apparel retailer Express (EXPR) gained in double digits intraday on December 2, after the company reported better-than-expected third-quarter earnings. However, given continuing supply chain disruptions and surging market volatility, will EXPR be able to maintain its growth trajectory in the near term? Read more to find out.
4 Cannabis Stock to Avoid in December
Amid the rising concerns regarding the rapid spread of the omicron coronavirus variant and skyrocketing inflation levels, cannabis legalization at the federal level doesn’t seem to be a top priority of the government right now. Thus, fundamentally weak cannabis stocks Green Thumb Industries (GTBIF), Canopy Growth (CGC), Planet 13 Holdings (PLNHF), and Flora Growth (FLGC) might witness a sharp pullback given the market volatility. So, these stocks are best avoided now.
2 Software Stocks to Buy, 2 to Sell
The software industry is expected to grow rapidly in the upcoming year, driven by the remote and hybrid working environment and increased tech integration across various industries. Thus, quality stocks Oracle (ORCL) and VMware (VMW) could deliver substantial gains. However, as the markets are extremely volatile, fundamentally weak software stocks OKTA (OKTA) and ZoomInfo Technologies (ZI) are best avoided now.
Is Pinduoduo a Buy Under $60?
Pinduoduo (PDD) is one of China’s fastest-growing e-commerce companies, with more than 700 million average active users. But though analysts expect the company to grow at an accelerated pace in the near term, is PDD a buy at its current price after the SEC adopted the Holding Foreign Companies Accountable Act yesterday? Read more to find out.
Is Pure Storage a Winner in the Computer Hardware Industry?
The shares of leading data storage provider Pure Storage (PSTG) have surged in price over the past few months, reflecting bullish investor sentiment. However, amid current market volatility due in degrees to the resurgence of COVID-19 cases and an ongoing global semiconductor shortage, will PSTG be able to maintain its bull run in the near future? Read more to find out.
Is Biofrontera a Good Pharmaceuticals Stock to Own?
Biofrontera (BFRI) is the publicly traded subsidiary of German biopharmaceutical company Biofrontera AG that specializes in dermatology products. The company went public through a traditional IPO on Oct. 29, but its shares have been losing momentum since. So, will BFRI be able to leverage its unique product portfolio to boost its growth trajectory amid the current public health crisis? Read more to find out.